CollPlant VP Legal granted 201K RSUs vesting to 2031

CollPlant’s VP Legal received a large time-based RSU award that vests through 2031, with share figures adjusted for a 1-for-10 reverse split.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd (symbol: CLGN) is the issuer of record for a Form 4 filing submitted to the SEC. Abelis Bar Berta reported acquisition or exercise transactions in this Form 4 filing.

CollPlant Biotechnologies Ltd (CLGN) reported that its VP Legal, Abelis Bar Berta, received a grant of 201,141 restricted share units (RSUs) on September 3, 2026. Thirty percent of the RSUs vest on September 3, 2027, with the remaining 70% vesting quarterly over four years through September 3, 2031, subject to continued service. After this award, the reporting person holds 206,441 ordinary-share interests, including shares and RSUs. A 1-for-10 reverse stock split effective September 4, 2026 is reflected in the reported amounts, and no Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Grant/Award: 201,141 shares

Grant/Award 1 txn

Insider Abelis Bar Berta

Role VP Legal

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2, F3	201,141	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 206,441 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.
2. F2. Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
3. F3. The total reported in Column 5 includes (i) 201,141 newly-awarded RSUs, (ii) 731 Ordinary Shares, and (iii) 4,569 previously-awarded RSUs.

Key Figures

RSUs granted: 201,141 RSUs Total holdings after transaction: 206,441 ordinary-share interests Existing ordinary shares: 731 shares +4 more

7 metrics

RSUs granted 201,141 RSUs Grant to VP Legal Abelis Bar Berta on September 3, 2026

Total holdings after transaction 206,441 ordinary-share interests Includes newly-awarded RSUs, existing shares, and previously-awarded RSUs

Existing ordinary shares 731 shares Portion of total holdings after the RSU grant

Previously-awarded RSUs 4,569 RSUs Part of total 206,441 ordinary-share interests after the grant

Reverse stock split ratio 1-for-10 Reverse stock split of ordinary shares effective September 4, 2026

Initial vesting tranche 30% of 201,141 RSUs Vests on September 3, 2027, subject to continued service

Remaining vesting period 4 years of quarterly installments Covers the remaining 70% of RSUs through September 3, 2031

Key Terms

restricted share units ("RSUs"), vesting schedule, reverse stock split, contingent right, +1 more

5 terms

restricted share units ("RSUs") financial

"The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent"

vesting schedule financial

"The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%)"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

reverse stock split financial

"the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

contingent right financial

"each represents a contingent right to receive one ordinary share"

ordinary share financial

"receive one ordinary share, no par value per share, of the Issuer"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

FAQ

What insider transaction did CLGN report for its VP Legal Abelis Bar Berta?

CollPlant reported that VP Legal Abelis Bar Berta received a grant of 201,141 RSUs on September 3, 2026. The RSUs each represent a contingent right to receive one ordinary share of CollPlant, with vesting spread from 2027 through 2031, subject to continued service.

How do the 201,141 RSUs granted at CLGN vest over time?

Of the 201,141 RSUs, 30% vest on September 3, 2027. The remaining 70% vest in equal installments every three months over the following four years, so they are fully vested on September 3, 2031, assuming continued service to CollPlant through each vesting date.

What are the total CLGN holdings reported for Abelis Bar Berta after this Form 4?

After the award, total holdings reported are 206,441 ordinary-share interests. This consists of (i) 201,141 newly-awarded RSUs, (ii) 731 ordinary shares, and (iii) 4,569 previously-awarded RSUs, all adjusted for the reverse stock split.

Did the CLGN insider RSU grant involve any cash price per share?

The Form 4 shows a per-share price of $0.00 for the 201,141 RSUs, indicating a compensation-related grant rather than a market purchase. Each RSU is a contingent right to receive one ordinary share upon vesting, subject to continued service.

How did CollPlant’s 1-for-10 reverse stock split affect this Form 4 data for CLGN?

Effective September 4, 2026, CollPlant implemented a 1-for-10 reverse stock split of its ordinary shares. The Form 4 states that the amounts of securities reported have been adjusted to reflect the reverse stock split, so all share figures are post-split.

Was the CLGN insider RSU grant made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating that the grant was made pursuant to a Rule 10b5-1 trading plan. The transaction is reported simply as a grant or award acquisition of RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:06 PM Accepted by SEC EDGAR 09/08/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abelis Bar Berta

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Legal

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/03/2026		A		201,141(2)	A	$0	206,441(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.

2. Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

3. The total reported in Column 5 includes (i) 201,141 newly-awarded RSUs, (ii) 731 Ordinary Shares, and (iii) 4,569 previously-awarded RSUs.

	/s/ Bar Berta Abelis	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)